Home
GUTS
GUTS News

Latest FRACTYL HEALTH INC (GUTS) News on December 18, 2024

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

GlobeNewswire

6 days ago

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

GlobeNewswire

9 days ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Fractyl Health to Participate in the Upcoming December Conferences

GlobeNewswire

22 days ago

Fractyl Health to Participate in the Upcoming December Conferences

Fractyl Health Third Quarter 2024 Earnings: US$0.48 loss per share (vs US$9.61 loss in 3Q 2023)

Simply Wall St.

a month ago

Fractyl Health Third Quarter 2024 Earnings: US$0.48 loss per share (vs US$9.61 loss in 3Q 2023)

Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

a month ago

Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates

Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024

GlobeNewswire

a month ago

Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024

Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024

GlobeNewswire

a month ago

Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024

Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024

GlobeNewswire

2 months ago

Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024

Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024

GlobeNewswire

2 months ago

Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024

Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference

GlobeNewswire

3 months ago

Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference

Fractyl Health to Participate in Upcoming September Investor Conferences

GlobeNewswire

3 months ago

Fractyl Health to Participate in Upcoming September Investor Conferences

Fractyl Health Second Quarter 2024 Earnings: US$0.36 loss per share (vs US$14.56 loss in 2Q 2023)

Simply Wall St.

4 months ago

Fractyl Health Second Quarter 2024 Earnings: US$0.36 loss per share (vs US$14.56 loss in 2Q 2023)

Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

4 months ago

Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates

Rising diabetes rates spur growth in weight management solutions

Medical Device Network

4 months ago

Rising diabetes rates spur growth in weight management solutions

Fractyl Health touts positive year-long weight loss results for Revita device

Clinical Trials Arena

4 months ago

Fractyl Health touts positive year-long weight loss results for Revita device

Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure

GlobeNewswire

4 months ago

Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure

Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024

GlobeNewswire

4 months ago

Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024

MT Newswires

5 months ago

Fractyl Health Gets FDA Breakthrough Device Designation for Weight Maintenance Procedure

Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs

GlobeNewswire

5 months ago

Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs

FDA expands Fractyl endoscopy trial to include untreated diabetes patients

Medical Device Network

6 months ago

FDA expands Fractyl endoscopy trial to include untreated diabetes patients

Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day

GlobeNewswire

6 months ago

Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day

Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates

GlobeNewswire

6 months ago

Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates

MT Newswires

6 months ago

Fractyl Health Says Potential Diabetes, Obesity Treatment Performed Well in Preclinical Trial

Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions

GlobeNewswire

6 months ago

Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions

Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions

GlobeNewswire

7 months ago

Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions

Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024

GlobeNewswire

7 months ago

Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024

Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

7 months ago

Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates

MT Newswires

7 months ago

Fractyl Health Says New Revita Data Show Sustained Weight Loss, Glucose Control in Type 2 Diabetes

Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)

GlobeNewswire

7 months ago

Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)

Fractyl Health to Present at BofA Securities 2024 Health Care Conference

GlobeNewswire

7 months ago

Fractyl Health to Present at BofA Securities 2024 Health Care Conference

Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024

GlobeNewswire

7 months ago

Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024

Fractyl Health, Inc.'s (NASDAQ:GUTS) largest shareholders are private equity firms with 52% ownership, individual investors own 30%

Simply Wall St.

8 months ago

Fractyl Health, Inc.'s (NASDAQ:GUTS) largest shareholders are private equity firms with 52% ownership, individual investors own 30%

Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting

GlobeNewswire

8 months ago

Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

GlobeNewswire

9 months ago

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire

9 months ago

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

GlobeNewswire

9 months ago

Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

GlobeNewswire

9 months ago

UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

GlobeNewswire

9 months ago

Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Analysts Bet Big on These Beaten-Down IPO Stocks

TipRanks

10 months ago

Analysts Bet Big on These Beaten-Down IPO Stocks

Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

GlobeNewswire

10 months ago

Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

Argus Research

10 months ago

Daily – Vickers Top Buyers & Sellers for 02/07/2024

Fractyl Health Announces Pricing of Initial Public Offering

GlobeNewswire

a year ago

Fractyl Health Announces Pricing of Initial Public Offering

Share on Social Networks: